Study number:
DF VOD-2013-03-REG
Short title:
VOD REGISTRY
Study status:
COLLECTING DATA, NOT RECRUITING
Deadline for data collection:
Study design:
Prospective, multinational study - 1 cohort (under defibrotide)
Primary objective:
The main objective of the registry is to assess the incidence rate of specific serious adverse events (SAEs) of interest (including fatalities) in patients with severe hepatic VOD post-HSCT treated with Defitelio®
Key inclusion criteria:
- Any consenting patient with a diagnosis of severe VOD post-HSCT (treated with defibrotide)
- Any consenting patient receiving defibrotide for any other condition (VOD Prophylaxis, non-severe VOD…) in HSCT context
- Any consenting patient receiving defibrotide for any other condition (VOD Prophylaxis, non-severe VOD…) in HSCT context
Country:
France
Italy
Portugal
United Kingdom
Principal investigator:
Pr Mohamad Mohty
Principal investigator email:
EBMT Study coordinator:
Jessica Lemaitre
Study coordinator email:
jessica.lemaitre@upmc.fr